Pain Solutions with DLss Biomarkers



At LasMed, we are revolutionizing the way pain is understood and treated with the Diode Laser Selective Stimulation (DLss) platform providing reliable, mechanistic biomarkers for pain. DLss enables a deeper understanding of neuropathic pain, improves the accuracy of pain assessments, accelerates the development of effective pain treatments, pain patient phenotyping, stratification, and provides insight into personalized treatment. Our solutions bridge the gap between preclinical and clinical research, offering a unique, cross-species translatable platform for pain management and therapy development.



Key Solutions Offered by DLss:



  1. Accurate Pain Assessment


    DLss allows for selective stimulation of pain fibers with precise control over stimulation parameters such as output laser intensity, beam diameter, and duration of stimulation that provides high reproducibility. Unlike traditional methods, DLss can target specific nerve fibers (C-or Aδ- polymodal fibers as well as silent C mechano-insensitive fibers) involved in pain signaling, providing highly accurate pain thresholds and neurogenic flare measurements. This precision enables better differentiation between different pain types, making DLss ideal for diagnosing neuropathic pain in clinical settings.


  2. Reliable Pain Biomarkers for Drug Development


    DLss is a powerful tool for evaluating analgesic efficacy during preclinical trials and clinical studies. Our biomarkers, based on C-fiber and Aδ-fiber thresholds, axon reflex flare responses, and pain detection thresholds, provide reliable, reproducible measures of pain responses. This tool enhances the evaluation of novel analgesics and accelerates their path to market.


  3. Cross-Species Translatability


    One of the most powerful features of DLss is its cross-species translatability. The platform has been validated across a variety of species, including rodents, pigs, monkeys, and humans. This consistency in results across species enables researchers to conduct studies in preclinical models that translate directly to human pain responses, making DLss an invaluable tool for both basic and translational pain research.


  4. Personalized Pain Profiling and Treatment


    With DLss, we can provide personalized pain profiles for patients, helping clinicians understand the unique mechanisms of pain in each individual. This information is critical for tailoring pain management strategies and improving treatment outcomes. DLss also enables the monitoring of pain response over time, allowing for adjustments to therapies as needed.


  5. Non-Invasive and Reliable Testing


    DLss uses a non-contact, non-invasive, fiber-optic laser-based method to induce selective pain stimulation, offering a safe and comfortable alternative to traditional pain testing procedures. It is also highly reproducible, ensuring consistency across tests and time points. This makes DLss a reliable tool for longitudinal pain monitoring and tracking the treatment progress.



Applications



  • Pain Mechanism Research: Study the role of specific pain fibers and their contribution to various pain conditions.


  • Analgesic Development: Evaluate the efficacy of new pain drugs and treatments, from preclinical to clinical stages.


  • Patient Stratification: Select the patient subgroup for whom developing pain treatment is expected to be effective and use it for clinical trial recruitment and recommendations after FDA approval of the treatment.


  • Personalized Pain Management: Tailor treatments based on individual pain profiles and monitor progress over time.



Why Choose DLss?


  • Proven Reliability: DLss provides reliable, reproducible data across species, making it an essential tool for both preclinical and clinical research.


  • Cross-Species Validation: From rodents to humans, DLss offers a consistent and translatable biomarker platform for pain research and clinical applications.


  • Mechanistic Insight: Unlike subjective pain scales, DLss is based on measurable, mechanistic biomarkers that directly correlate with pain pathways and nerve activity.


  • Regulatory Support: DLss biomarkers are currently undergoing clinical trials, with the goal of advancing toward regulatory review for use in pain management and treatment efficacy monitoring.



Partner with Us

LasMed is committed to advancing pain research and improving patient outcomes through innovative biomarker technology. Our DLss platform provides the scientific rigor and clinical relevance needed to address the complex challenges of pain management.

Contact us today to learn how DLss can transform your pain research, drug development, and clinical trials.

FDA Disclaimer

The information provided on this website is for informational purposes only and is not intended to be used as medical advice. The products and technologies described herein, including the DLss platform and associated biomarkers, have not been reviewed or approved by the U.S. Food and Drug Administration (FDA) for clinical use or treatment purposes unless otherwise specified. Any references to clinical applications, trials, or therapeutic efficacy are based on ongoing research and preclinical or early clinical data, and outcomes may vary. These products are intended for research use only and are not intended for use in diagnosing, treating, curing, or preventing any disease or medical condition.